Pembrolizumab with carboplatin and paclitaxel is in development for the treatment of endometrial cancer (cancer of the womb lining) when it has started to spread to other parts of the body (advanced) or has come back after initial treatment (recurrent). Symptoms of endometrial cancer can include abnormal vaginal bleeding, pelvic pain, painful urination or pain during sex. Cancer that recurs or has spread is harder to treat, and the aim of treatment is usually to control symptoms and if possible, limit cancer progression. There is a need for treatments that provide longer-lasting positive outcomes for women with advanced or recurrent endometrial cancer.
Pembrolizumab with chemotherapy for treating advanced or recurrent endometrial cancer
Pembrolizumab with carboplatin and paclitaxel is in development for the treatment of endometrial cancer (cancer of the womb lining) when it has started to spread to other parts of the body (advanced) or has come back after initial treatment (recurrent). Symptoms of endometrial cancer can include abnormal vaginal bleeding, pelvic pain, painful urination or pain during sex.